Biond is developing biological therapies and is at the forefront of research of immune-evasion mechanisms and its translation into novel cancer therapeutics.
Our pipeline is based on advanced in-house, cutting-edge research capabilities and access to fresh tumor and blood samples from cancer patients
Our preclinical and clinical programs include:
- BND-22, a novel, first-in-class immune checkpoint inhibitor targeting the ILT2 (LILRB1) receptor which was partnered with Sanofi and is currently being studied in a phase 1 clinical trial
- BND-35 - A monoclonal antibody targeting Immunoglobulin-like transcript 3 (ILT3), is in advanced pre-clinical stages. BND-35 is planned to enter Phase 1 clinical trials in Q1 2024.
- BND-67 - A nanobody based agent that targets CD28 shedding - a novel immune-regulatory mechanism found in cancer patients that serves as a resistance mechanism to anti-PD-1 therapy